|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
3
|
Resverlogix Corp.
|
Jun 14, 2019 11:23AM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
2
|
Resverlogix Corp.
|
Jun 14, 2019 11:30AM
|
|
Re: Random thoughts RVX-208 and COVID-19
|
6
|
Resverlogix Corp.
|
Apr 12, 2020 09:47PM
|
|
Re: RAAS Inhibitors in Patients with Covid-19
|
4
|
Resverlogix Corp.
|
Mar 31, 2020 10:58AM
|
|
Re: Question to ask at the AGM
|
3
|
Resverlogix Corp.
|
Oct 31, 2019 01:35PM
|
|
Re: PAH Plans get a write up in Pulmonary Hypertension News
|
8
|
Resverlogix Corp.
|
May 21, 2019 01:15PM
|
|
Re: orphan diseases
|
2
|
Resverlogix Corp.
|
Jul 05, 2018 11:45PM
|
|
Re: orphan diseases
|
8
|
Resverlogix Corp.
|
Jul 01, 2018 03:13PM
|
|
Re: Off-label drug use in Canada and the USA
|
5
|
Resverlogix Corp.
|
Feb 05, 2021 06:51PM
|
|
Re: Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
1
|
Resverlogix Corp.
|
Sep 16, 2019 02:38PM
|
|
Re: Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
1
|
Resverlogix Corp.
|
Sep 16, 2019 03:37PM
|
|
Re: Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
3
|
Resverlogix Corp.
|
Sep 16, 2019 04:27PM
|
|
Re: Not much happening these days regarding share price
|
4
|
Resverlogix Corp.
|
Apr 10, 2019 02:41PM
|
|
Re: No mention of efficacy again...
|
5
|
Resverlogix Corp.
|
Mar 27, 2019 01:44PM
|
|
Re: New Alkaline Phosphate publication from Dr. Kalantar-Zadeh
|
3
|
Resverlogix Corp.
|
Nov 17, 2019 12:29PM
|
|
Re: New Alkaline Phosphate publication from Dr. Kalantar-Zadeh
|
5
|
Resverlogix Corp.
|
Nov 17, 2019 01:01PM
|
|
Re: My New Year's wish if for RVX to get a deal structured similarly to MYOV...
|
7
|
Resverlogix Corp.
|
Dec 29, 2020 05:08PM
|
|
Re: My general impressions
|
5
|
Resverlogix Corp.
|
Nov 16, 2019 04:11PM
|
|
Re: My general impressions
|
8
|
Resverlogix Corp.
|
Nov 16, 2019 04:38PM
|
|
Re: MACE Event rate,....
|
3
|
Resverlogix Corp.
|
Feb 28, 2019 01:40PM
|
